Oncology · Urology
Prostate Cancer
Care in London
From first PSA concern through to diagnosis, treatment and long-term follow-up — all managed by Mr Ameen personally, with honest, evidence-based guidance at every step.
From Diagnosis to Treatment: The Journey
PSA Testing & Initial Assessment
If your PSA is raised or you have symptoms, Mr Ameen will assess your PSA trend, perform a clinical examination and arrange a multiparametric MRI (mpMRI) — the most accurate non-invasive test for prostate cancer.
MRI-Fusion Targeted Biopsy
If the MRI identifies a suspicious area (PIRADS 3–5), Mr Ameen performs an MRI-fusion targeted biopsy — combining MRI and ultrasound images in real-time to sample precisely the area of concern. Far more accurate than random biopsy.
Staging & Risk Assessment
Your cancer is staged based on biopsy results (Gleason score, number of positive cores), PSA level and MRI findings. A PSMA PET-CT scan may be arranged to exclude spread to lymph nodes or bone.
Active Surveillance
For low-risk, localised cancers (Gleason 6, PSA <10), active surveillance — regular monitoring without immediate treatment — avoids unnecessary side effects while maintaining the option of curative treatment if needed.
Robotic Prostatectomy
For localised intermediate and high-risk cancers, robotic radical prostatectomy is often the preferred surgical treatment. Mr Ameen has performed over 500 cases using the Retzius-sparing technique. Learn more →
Radiotherapy & Systemic Treatment
External beam radiotherapy (with or without hormone therapy) is an alternative to surgery for suitable patients. Mr Ameen co-ordinates seamlessly with clinical oncology colleagues to ensure all options are presented and the right path is chosen.
Understanding Prostate Cancer in the UK
Prostate cancer is the most common cancer in men in the UK. Over 55,000 men are diagnosed each year. Caught at an early stage, it is highly treatable — often curable. The challenge is that early prostate cancer usually has no symptoms at all.
Risk factors
Age — the single biggest risk factor. Prostate cancer is rare under 50 and increasingly common from 60 onwards. The average age at diagnosis in the UK is 69.
Family history — having a father or brother with prostate cancer more than doubles your risk. A family history of BRCA2 mutation is particularly significant and warrants earlier, more intensive screening.
Ethnicity — Black men have a significantly higher lifetime risk of prostate cancer compared to white men and typically develop it at a younger age. Screening from the age of 45 is recommended for Black men with a family history.
Diet and lifestyle — high-fat Western diets and obesity are associated with more aggressive disease. The evidence for specific dietary modifications is still evolving.
Grades and stages explained
Gleason / ISUP grade — the biopsy assigns a grade based on how abnormal the cancer cells look. ISUP grade 1 (Gleason 6) is low-risk and often managed with active surveillance. Grades 2–5 require active treatment in most cases.
Stage — staging defines how far the cancer has spread. T1–T2 cancers are confined to the prostate (localised). T3 cancers extend outside the prostate capsule. T4 cancers invade adjacent structures. N1 or M1 disease involves lymph nodes or distant spread.
PSA density and kinetics — the speed at which PSA rises (PSA velocity) and the PSA level relative to prostate volume (PSA density) help distinguish aggressive from indolent disease and guide biopsy decisions alongside MRI findings.
Living Well with a Prostate Cancer Diagnosis
Active surveillance: not "doing nothing"
For low-risk prostate cancer, active surveillance is a deliberate strategy of monitoring the cancer closely — with regular PSA tests, MRI scans and repeat biopsies — to intervene only if the disease progresses. It avoids the side effects of immediate treatment while ensuring progression is caught early. Mr Ameen has extensive experience managing men on active surveillance protocols and follows NICE guidelines for monitoring frequency and escalation thresholds.
Side effect management after treatment
The main side effects of radical prostatectomy are temporary urinary incontinence and erectile dysfunction. With the Retzius-sparing nerve-sparing technique, the vast majority of men regain urinary continence within 3–6 months and erectile function within 6–18 months, particularly in younger men with pre-existing function. A dedicated penile rehabilitation programme including PDE5 inhibitors is started from the day of catheter removal. Pelvic floor physiotherapy is recommended for all patients before and after surgery.
Prostate Cancer FAQs
Facing a prostate cancer diagnosis? Don't navigate it alone.
Clear, honest, consultant-led advice — from PSA concern to surgical cure. Book an appointment to discuss your individual situation.